Chugai Pharmaceutical : Supplementary Materials for Consolidated Financial Results for the 1st Quarter of Fiscal Year 2021. 12 (IFRS)

Supplementary Materials for

Consolidated Financial Results for

the 1st Quarter of Fiscal Year 2021. 12 (IFRS)

Chugai Pharmaceutical co., ltd.

Notes: 1. Portions of this report that refer to performance forecasts or any other future events are believed to be reasonable under information available at the time of the forecasts. Actual results may materially differ from these forecasts due to potential risks and uncertainties.

1. Amounts shown in this report are rounded to the nearest 0.1 billion yen. Variance and % are calculated based on the amounts shown.
2. Exchange rates used for each period are as follows.

QTR											(Yen)
			Actual*					Actual*
			FY2020					FY2021
		1-3	4-6		7-9	10-12	1-3	4-6		7-9	10-12
		QTR	QTR		QTR	QTR	QTR	QTR		QTR	QTR
CHF		112.61	111.54		115.39	115.52	117.08
EUR		120.19	118.35		124.06	124.51	127.65
USD		109.02	107.53		106.16	104.50	105.83
SGD		78.72	76.15		77.23	77.58	79.47
*Market average exchange rate
YTD
	Actual*		Actual*					Actual*		Assumption
	FY2019		FY2020					FY2021		FY2021
	1-12	1-3	1-6		1-9	1-12	1-3	1-6		1-9	1-12	1-12
	Full-year	YTD	YTD		YTD	Full-year	YTD	YTD		YTD	Full-year	Full-year
CHF	109.72	112.61	112.07		113.14	113.72	117.08					116.00
EUR	122.08	120.19	119.27		120.80	121.69	127.65					126.00
USD	109.05	109.02	108.28		107.57	106.80	105.83					105.00
SGD	79.94	78.72	77.42		77.36	77.41	79.47					78.00
*Market average exchange rate
Period-end
	Actual		Actual					Actual
	FY2019		FY2020					FY2021
	31 Dec.	31 Mar.	30 Jun.		30 Sep.	31 Dec.	31 Mar.	30 Jun.		30 Sep.	31 Dec.
CHF	112.31	112.49	113.07		114.92	117.10	117.14
EUR	121.93	119.13	120.93		124.08	126.89	129.30
USD	108.88	107.83	107.57		105.66	103.19	110.37
SGD	80.72	75.73	77.18		77.19	77.98	81.87

Chugai Pharmaceutical Co., Ltd. (4519) Supplementary Materials for Consolidated Financial Results for the 1st quarter of FY2021(IFRS)

1

Reconciliation of IFRS results to Core results

										(Billions of yen)
			FY2020			FY2021
			1-3				1-3
		IFRS results	Intangible		Others	Core results	IFRS results	Intangible		Others	Core results
			assets					assets
Revenues	179.4	-		-	179.4	168.8	-		-	168.8
	Sales	144.5	-		-	144.5	130.3	-		-	130.3
	Royalties and other operating income	34.9	-		-	34.9	38.6	-		-	38.6
Cost of sales	(61.3)	0.3		-	(61.0)	(55.3)	0.3		-	(55.0)
Gross profit	118.2	0.3		-	118.5	113.5	0.3		-	113.8
Operatingexpenses	(45.7)	0.2		1.2	(44.4)	(49.5)	0.0		1.1	(48.5)
	Marketing and distribution	(15.8)	-		0.3	(15.5)	(15.9)	-		0.0	(15.8)
	Research and development	(26.1)	0.2		0.9	(25.0)	(29.7)	0.0		1.0	(28.7)
	General and administration	(3.9)	-		-	(3.9)	(3.9)	-		0.0	(3.9)
Operating profit	72.4	0.5		1.2	74.1	64.0	0.3		1.1	65.4
	Financing costs	(0.0)	-		-	(0.0)	(0.0)	-		-	(0.0)
	Other financial income (expense)	(0.6)	-		-	(0.6)	0.3	-		-	0.3
	Other expense	(0.5)	-		-	(0.5)	-	-		-	-
Profitbefore taxes	71.2	0.5		1.2	72.9	64.2	0.3		1.1	65.6
Income taxes	(19.7)	(0.1)		(0.3)	(20.2)	(16.8)	(0.1)		(0.3)	(17.2)
Net income	51.5	0.3		0.8	52.7	47.4	0.2		0.8	48.4
Attributable to
	Chugai shareholders	51.5	0.3		0.8	52.7	47.4	0.2		0.8	48.4
	Non-controlling interests	-	-		-	-	-	-		-	-

Core results

Chugai discloses its results on a Core basis from 2013 in conjunction with its transition to IFRS. Core results are the results after adjusting non-recurring items recognized by Chugai to IFRS results, and are consistent with the Core concept disclosed by Roche. Core results are used by Chugai as an internal performance indicator, for explaining the status of recurring profits both internally and externally, and as the basis for payment-by-results.

The table above shows the reconciliation of IFRS results into Core results. The detail is as below.

Intangible assets

Amortization （0.4 billion yen in 2020 and 0.3 billion yen in 2021)

Impairment （0.1 billion yen in 2020 and none in 2021）

Others

Restructuring expenses （1.2 billion yen in 2020 and 1.1 billion yen in 2021）

		Chugai Pharmaceutical Co., Ltd. (4519) Supplementary Materials for Consolidated Financial Results for the 1st quarter of FY2021(IFRS)	2
IFRS results (QTR)
			3	4		5	6								(Billions of yen)
				Actual						Actual
				FY2020						FY2021
			1-3	4-6		7-9	10-12	1-3	Change	4-6	Change		7-9	Change	10-12	Change
			QTR	QTR		QTR	QTR	QTR	(%)	QTR	(%)		QTR	(%)	QTR	(%)
Revenues	179.4	188.7		208.4	210.4	168.8	(5.9)
	Sales	144.5	161.1		159.1	168.5	130.3	(9.8)
		Domestic	101.9	102.7		98.6	105.9	94.9	(6.9)
		Overseas	42.6	58.4		60.6	62.6	35.4	(16.9)
	Royalties and other operating income	34.9	27.6		49.3	41.9	38.6	+10.6
		Royalty and profit-sharing income	26.4	27.1		35.6	40.5	36.6	+38.6
		Other operating income	8.5	0.5		13.6	1.4	2.0	(76.5)
Cost of sales	(61.3)	(70.6)		(69.4)	(72.3)	(55.3)	(9.8)
		(% of Sales)	42.4	43.8		43.6	42.9	42.4	-
Gross profit	118.2	118.1		139.0	138.2	113.5	(4.0)
		(% of Revenues)	65.9	62.6		66.7	65.7	67.2	-
Operating expenses	(45.7)	(49.9)		(52.4)	(64.2)	(49.5)	+8.3
		(% of Revenues)	25.5	26.4		25.1	30.5	29.3	-
	Marketing and distribution	(15.8)	(17.0)		(17.0)	(22.8)	(15.9)	+0.6
		(% of Revenues)	8.8	9.0		8.2	10.8	9.4	-
	Research and development	(26.1)	(28.8)		(30.1)	(32.8)	(29.7)	+13.8
		(% of Revenues)	14.5	15.3		14.4	15.6	17.6	-
	General and administration	(3.9)	(4.1)		(5.2)	(8.6)	(3.9)	0.0
		(% of Revenues)	2.2	2.2		2.5	4.1	2.3	-
Operating profit	72.4	68.2		86.7	73.9	64.0	(11.6)
		(% of Revenues)	40.4	36.1		41.6	35.1	37.9	-
	Financing costs	(0.0)	(0.0)		(0.0)	(0.0)	(0.0)	0.0
	Other financial income (expense)	(0.6)	0.5		(0.8)	(0.5)	0.3	-
	Other expense	(0.5)	(0.3)		(0.3)	(0.4)	-	-
Profit before taxes	71.2	68.4		85.6	73.1	64.2	(9.8)
		(% of Revenues)	39.7	36.2		41.1	34.7	38.0	-
Income taxes	(19.7)	(17.6)		(25.4)	(20.7)	(16.8)	(14.7)
Net income	51.5	50.8		60.1	52.3	47.4	(8.0)
		(% of Revenues)	28.7	26.9		28.8	24.9	28.1	-
Attributable to
	Chugai shareholders	51.5	50.8		60.1	52.3	47.4	(8.0)
	Non-controlling interests	-	-		-	-	-	-
Earnings per share
	Basic (yen)	31.37	30.89		36.58	31.82	28.84	(8.1)
	Diluted (yen)	31.33	30.85		36.55	31.80	28.82	(8.0)

Other financial income (expense) includes net amount of FX related gains/losses.

Effective July 1, 2020, Chugai Pharmaceutical Co., Ltd. ("Chugai") implemented a three-for-one stock split of its common stock. "Earnings per share (Basic)" and "Earnings per share (Diluted)" presents the amount after the stock split.

		Chugai Pharmaceutical Co., Ltd. (4519) Supplementary Materials for Consolidated Financial Results for the 1st quarter of FY2021(IFRS)	3
IFRS results (YTD)
			2	3												(Billions of yen)
			Actual		Actual						Actual
			FY2019		FY2020						FY2021
			1-12	1-3	1-6		1-9	1-12	1-3	Change	1-6	Change		1-9	Change	1-12	Change
			YTD	YTD	YTD		YTD	YTD	YTD	(%)	YTD	(%)		YTD	(%)	YTD	(%)
Revenues	686.2	179.4	368.1		576.5	786.9	168.8	(5.9)
	Sales	588.9	144.5	305.7		464.8	633.3	130.3	(9.8)
		Domestic	437.6	101.9	204.6		303.2	409.1	94.9	(6.9)
		Overseas	151.3	42.6	101.0		161.6	224.2	35.4	(16.9)
	Royalties and other operating income	97.3	34.9	62.5		111.7	153.6	38.6	+10.6
		Royalty and profit-sharing income	76.5	26.4	53.5		89.1	129.6	36.6	+38.6
		Other operating income	20.8	8.5	9.0		22.6	24.1	2.0	(76.5)
Cost of sales	(266.1)	(61.3)	(131.8)		(201.2)	(273.5)	(55.3)	(9.8)
		(% of Sales)	45.2	42.4	43.1		43.3	43.2	42.4	-
Gross profit	420.1	118.2	236.3		375.3	513.5	113.5	(4.0)
		(% of Revenues)	61.2	65.9	64.2		65.1	65.3	67.2	-
Operating expenses	(209.5)	(45.7)	(95.7)		(148.0)	(212.3)	(49.5)	+8.3
		(% of Revenues)	30.5	25.5	26.0		25.7	27.0	29.3	-
	Marketing and distribution	(77.2)	(15.8)	(32.8)		(49.8)	(72.6)	(15.9)	+0.6
		(% of Revenues)	11.3	8.8	8.9		8.6	9.2	9.4	-
	Research and development	(107.9)	(26.1)	(54.9)		(85.0)	(117.9)	(29.7)	+13.8
		(% of Revenues)	15.7	14.5	14.9		14.7	15.0	17.6	-
	General and administration	(24.4)	(3.9)	(8.0)		(13.2)	(21.8)	(3.9)	0.0
		(% of Revenues)	3.6	2.2	2.2		2.3	2.8	2.3	-
Operating profit	210.6	72.4	140.6		227.3	301.2	64.0	(11.6)
		(% of Revenues)	30.7	40.4	38.2		39.4	38.3	37.9	-
	Financing costs	(0.1)	(0.0)	(0.0)		(0.0)	(0.1)	(0.0)	0.0
	Other financial income (expense)	0.5	(0.6)	(0.2)		(1.0)	(1.5)	0.3	-
	Other expense	(3.1)	(0.5)	(0.9)		(1.1)	(1.5)	-	-
Profit before taxes	207.9	71.2	139.6		225.1	298.2	64.2	(9.8)
		(% of Revenues)	30.3	39.7	37.9		39.0	37.9	38.0	-
Income taxes	(50.3)	(19.7)	(37.3)		(62.7)	(83.5)	(16.8)	(14.7)
Net income	157.6	51.5	102.3		162.4	214.7	47.4	(8.0)
		(% of Revenues)	23.0	28.7	27.8		28.2	27.3	28.1	-
Attributable to
	Chugai shareholders	157.6	51.5	102.3		162.4	214.7	47.4	(8.0)
	Non-controlling interests	-	-	-		-	-	-	-
Earnings per share
	Basic (yen)	95.95	31.37	62.26		98.84	130.66	28.84	(8.1)
	Diluted (yen)	95.81	31.33	62.18		98.74	130.53	28.82	(8.0)

Other financial income (expense) includes net amount of FX related gains/losses.

Effective July 1, 2020, Chugai Pharmaceutical Co., Ltd. ("Chugai") implemented a three-for-one stock split of its common stock. "Earnings per share (Basic)" and "Earnings per share (Diluted)" presents the amount after the stock split.

		Chugai Pharmaceutical Co., Ltd. (4519) Supplementary Materials for Consolidated Financial Results for the 1st quarter of FY2021(IFRS)	4
Core results (QTR)
			3	4		5	6								(Billions of yen)
				Actual						Actual
				FY2020						FY2021
			1-3	4-6		7-9	10-12	1-3	Change	4-6	Change		7-9	Change	10-12	Change
			QTR	QTR		QTR	QTR	QTR	(%)	QTR	(%)		QTR	(%)	QTR	(%)
Revenues	179.4	188.7		208.4	210.4	168.8	(5.9)
	Sales	144.5	161.1		159.1	168.5	130.3	(9.8)
		Domestic	101.9	102.7		98.6	105.9	94.9	(6.9)
		Overseas	42.6	58.4		60.6	62.6	35.4	(16.9)
	Royalties and other operating income	34.9	27.6		49.3	41.9	38.6	+10.6
		Royalty and profit-sharing income	26.4	27.1		35.6	40.5	36.6	+38.6
		Other operating income	8.5	0.5		13.6	1.4	2.0	(76.5)
Cost of sales	(61.0)	(70.3)		(69.1)	(72.0)	(55.0)	(9.8)
		(% of Sales)	42.2	43.6		43.4	42.7	42.2	-
Gross profit	118.5	118.4		139.3	138.5	113.8	(4.0)
		(% of Revenues)	66.1	62.7		66.8	65.8	67.4	-
Operating expenses	(44.4)	(48.8)		(51.2)	(62.4)	(48.5)	+9.2
		(% of Revenues)	24.7	25.9		24.6	29.7	28.7	-
	Marketing and distribution	(15.5)	(16.8)		(16.7)	(22.5)	(15.8)	+1.9
		(% of Revenues)	8.6	8.9		8.0	10.7	9.4	-
	Research and development	(25.0)	(27.9)		(29.3)	(31.3)	(28.7)	+14.8
		(% of Revenues)	13.9	14.8		14.1	14.9	17.0	-
	General and administration	(3.9)	(4.1)		(5.2)	(8.6)	(3.9)	0.0
		(% of Revenues)	2.2	2.2		2.5	4.1	2.3	-
Operating profit	74.1	69.7		88.2	76.1	65.4	(11.7)
		(% of Revenues)	41.3	36.9		42.3	36.2	38.7	-
	Financing costs	(0.0)	(0.0)		(0.0)	(0.0)	(0.0)	0.0
	Other financial income (expense)	(0.6)	0.5		(0.8)	(0.5)	0.3	-
	Other expense	(0.5)	(0.3)		(0.3)	(0.4)	-	-
Profit before taxes	72.9	69.8		87.0	75.2	65.6	(10.0)
		(% of Revenues)	40.6	37.0		41.7	35.7	38.9	-
Income taxes	(20.2)	(18.0)		(25.9)	(21.4)	(17.2)	(14.9)
Net income	52.7	51.8		61.2	53.8	48.4	(8.2)
		(% of Revenues)	29.4	27.5		29.4	25.6	28.7	-
Attributable to
	Chugai shareholders	52.7	51.8		61.2	53.8	48.4	(8.2)
	Non-controlling interests	-	-		-	-	-	-
Core earnings per share (diluted) (yen)	32.04	31.47		37.17	32.71	29.42	(8.2)

Please see page 1 "Reconciliation of IFRS results to Core results" for the detail of the adjustments.

Core earnings per share (diluted) (yen) : Net income attributable to Chugai shareholders / Weighted average number of shares in issue used to calculate diluted earnings per share. Other financial income (expense) includes net amount of FX related gains/losses.

Effective July 1, 2020, Chugai Pharmaceutical Co., Ltd. ("Chugai") implemented a three-for-one stock split of its common stock. Core EPS presents the amount after the stock split.

		Chugai Pharmaceutical Co., Ltd. (4519) Supplementary Materials for Consolidated Financial Results for the 1st quarter of FY2021(IFRS)	5
Core results (YTD)
			6	6	6		6	6										(Billions of yen)
																		Forecast
			Actual		Actual						Actual					(Feb 4th
																		announced)
			FY2019		FY2020						FY2021					FY2021
			1-12	1-3	1-6		1-9	1-12	1-3	Change	1-6	Change		1-9	Change	1-12	Change	1-12	Change
			YTD	YTD	YTD		YTD	YTD	YTD	(%)	YTD	(%)		YTD	(%)	YTD	(%)	YTD	(%)
Revenues	686.2	179.4	368.1		576.5	786.9	168.8	(5.9)								800.0	+1.7
	Sales	588.9	144.5	305.7		464.8	633.3	130.3	(9.8)								631.0	(0.4)
		Domestic	437.6	101.9	204.6		303.2	409.1	94.9	(6.9)								393.7	(3.8)
		Overseas	151.3	42.6	101.0		161.6	224.2	35.4	(16.9)								237.3	+5.8
	Royalties and other operating income	97.3	34.9	62.5		111.7	153.6	38.6	+10.6								169.0	+10.0
		Royalty and profit-sharing income	76.5	26.4	53.5		89.1	129.6	36.6	+38.6								163.0	+25.8
		Other operating income	20.8	8.5	9.0		22.6	24.1	2.0	(76.5)								6.0	(75.1)
Cost of sales	(265.1)	(61.0)	(131.2)		(200.3)	(272.3)	(55.0)	(9.8)								(252.5)	(7.3)
		(% of Sales)	45.0	42.2	42.9		43.1	43.0	42.2	-								40.0	-
Gross profit	421.1	118.5	236.9		376.2	514.7	113.8	(4.0)								547.5	+6.4
		(% of Revenues)	61.4	66.1	64.4		65.3	65.4	67.4	-								68.4	-
Operating expenses	(196.2)	(44.4)	(93.2)		(144.3)	(206.7)	(48.5)	+9.2								(227.5)	+10.1
		(% of Revenues)	28.6	24.7	25.3		25.0	26.3	28.7	-								28.4	-
	Marketing and distribution	(73.5)	(15.5)	(32.3)		(49.0)	(71.5)	(15.8)	+1.9
		(% of Revenues)	10.7	8.6	8.8		8.5	9.1	9.4	-
	Research and development	(102.1)	(25.0)	(52.9)		(82.2)	(113.5)	(28.7)	+14.8								(131.5)	+15.9
		(% of Revenues)	14.9	13.9	14.4		14.3	14.4	17.0	-								16.4	-
	General and administration	(20.6)	(3.9)	(8.0)		(13.1)	(21.7)	(3.9)	0.0
		(% of Revenues)	3.0	2.2	2.2		2.3	2.8	2.3	-
Operating profit	224.9	74.1	143.7		231.9	307.9	65.4	(11.7)								320.0	+3.9
		(% of Revenues)	32.8	41.3	39.0		40.2	39.1	38.7	-								40.0	-
	Financing costs	(0.1)	(0.0)	(0.0)		(0.0)	(0.1)	(0.0)	0.0
	Other financial income (expense)	0.5	(0.6)	(0.2)		(1.0)	(1.5)	0.3	-
	Other expense	(3.1)	(0.5)	(0.9)		(1.1)	(1.5)	-	-
Profit before taxes	222.2	72.9	142.7		229.7	304.9	65.6	(10.0)
		(% of Revenues)	32.4	40.6	38.8		39.8	38.7	38.9	-
Income taxes	(54.6)	(20.2)	(38.2)		(64.1)	(85.5)	(17.2)	(14.9)
Net income	167.6	52.7	104.5		165.6	219.4	48.4	(8.2)								232.0	+5.7
		(% of Revenues)	24.4	29.4	28.4		28.7	27.9	28.7	-								29.0	-
Attributable to
	Chugai shareholders	167.6	52.7	104.5		165.6	219.4	48.4	(8.2)
	Non-controlling interests	-	-	-		-	-	-	-
Weighted average number of shares in
issue used to calculate diluted earnings per	1,645	1,645	1,645		1,645	1,645	1,645	0.0
share (Millions of shares)
Core earnings per share (diluted) (yen)	101.93	32.04	63.51		100.68	133.39	29.42	(8.2)								141.00	+5.7
Core payout ratio (%)	45.8					41.2										42.6	-
	Dividend per share (Full year) (yen)	140					-										60	-
	Dividend per share (Year end) (yen)	92					30										30	-
	Dividend per share (Half year) (yen)	48					75										30	-

Please see page 1 "Reconciliation of IFRS results to Core results" for the detail of the adjustments.

Core earnings per share (diluted) (yen) : Net income attributable to Chugai shareholders / Weighted average number of shares in issue used to calculate diluted earnings per share. Other financial income (expense) includes net amount of FX related gains/losses.

Effective July 1, 2020, Chugai Pharmaceutical Co., Ltd. ("Chugai") implemented a three-for-one stock split of its common stock. Core EPS presents the amount after the stock split. Weighted average number of shares in issue used to calculate diluted earnings per share presents the amount after the stock split.

The dividend for the fiscal year ended December 31, 2019 and the second quarter of the fiscal year 2020 presents the amount prior to the stock split.

The annual dividend per share for the fiscal year ended December 31, 2020 is not stated because the amounts cannot be simply combined due to the implementation of the stock split. The annual dividend per share is ¥165 when calculated based on the assumption of no stock split, and ¥55 when calculated with the stock split taken into account.

Chugai Pharmaceutical Co., Ltd. (4519) Supplementary Materials for Consolidated Financial Results for the 1st quarter of FY2021(IFRS)	6
Statements of revenues (QTR)
					Actual						Actual
					FY2020						FY2021
				1-3	4-6		7-9	10-12	1-3	Change	4-6	Change		7-9	Change	10-12	Change
				QTR	QTR		QTR	QTR	QTR	(%)	QTR	(%)		QTR	(%)	QTR	(%)
Sales	144.5	161.1		159.1	168.5	130.3	(9.8)
	Domestic	101.9	102.7		98.6	105.9	94.9	(6.9)
		Oncology	55.3	58.1		56.0	62.9	57.9	+4.7
			Avastin	20.4	20.4		19.7	21.1	18.8	(7.8)
			Tecentriq	7.8	8.8		8.9	12.0	14.1	+80.8
			Perjeta	8.3	8.4		8.1	8.7	7.4	(10.8)
			Alecensa	5.6	6.6		6.4	7.3	6.0	+7.1
			Kadcyla	2.1	2.5		2.6	3.1	3.2	+52.4
			Herceptin	4.5	4.1		3.7	3.6	2.6	(42.2)
			Gazyva	1.0	1.0		1.1	1.3	1.0	0.0
			Rituxan	1.9	1.8		1.8	1.8	1.2	(36.8)
			Xeloda	1.1	0.9		0.8	0.8	0.6	(45.5)
			Rozlytrek	0.0	0.1		0.1	0.2	0.1	-
			Foundation Medicine	0.6	0.6		0.8	0.9	1.0	+66.7
			Other products	2.0	2.8		2.1	2.1	1.8	(10.0)
		Primary	46.6	44.6		42.6	43.0	36.9	(20.8)
			Hemlibra	7.9	8.2		8.4	9.5	8.8	+11.4
			Actemra	9.5	9.7		9.4	10.7	9.2	(3.2)
			Edirol	8.8	9.5		5.9	3.6	2.9	(67.0)
			Mircera	4.2	4.3		4.5	4.6	3.4	(19.0)
			Bonviva	2.1	2.1		2.3	2.4	2.0	(4.8)
			CellCept	2.2	2.3		2.2	2.4	2.0	(9.1)
			Oxarol	1.4	1.6		1.6	1.7	1.4	0.0
			Enspryng	-	-		0.3	1.0	1.4	-
			Tamiflu(Ordinary use)	0.6	0.0		0.0	0.2	(0.1)	-
			Tamiflu(Govt. stockpiles etc.)	2.6	-		0.3	0.7	1.2	(53.8)
			Other products	7.2	7.0		7.7	6.0	4.7	(34.7)
	Overseas	42.6	58.4		60.6	62.6	35.4	(16.9)
			Hemlibra	8.6	7.9		5.1	4.5	8.5	(1.2)
			To Roche	8.2	7.5		4.7	4.2	8.0	(2.4)
			Actemra	24.1	36.5		37.0	36.8	17.4	(27.8)
			To Roche	23.5	35.9		36.5	36.0	16.9	(28.1)
			Alecensa	6.2	10.7		13.9	13.6	6.0	(3.2)
			To Roche	5.9	10.3		13.6	13.2	5.6	(5.1)
			Enspryng	0.1	0.3		1.1	4.0	-	-
			To Roche	0.1	0.3		1.1	4.0	-	-
			Neutrogin	2.5	2.0		2.3	2.3	2.2	(12.0)
			Other products	1.1	1.1		1.1	1.4	1.2	+9.1
Royalties and other operating income	34.9	27.6		49.3	41.9	38.6	+10.6
	Royalty and profit-sharing income	26.4	27.1		35.6	40.5	36.6	+38.6
	Other operating income	8.5	0.5		13.6	1.4	2.0	(76.5)
Revenues	179.4	188.7		208.4	210.4	168.8	(5.9)
	Domestic	109.5	102.7		100.6	106.2	95.3	(13.0)
	Overseas	69.9	86.0		107.8	104.3	73.6	+5.3

From the 1st Quarter of FY2021, sales for Foundation Medicine is included "Oncology", instead of "Others" until FY2020.

Also sales for products included "Bone and Joint", "Renal Diseases", "Others" until FY2020, are included "Primary" from the 1st Quarter of FY2021.

			Chugai Pharmaceutical Co., Ltd. (4519) Supplementary Materials for Consolidated Financial Results for the 1st quarter of FY2021(IFRS)	7
Statements of revenues (YTD)
																			(Billions of yen)
						Actual						Actual					Forecast
				Actual											(Feb 4th
																			announced)
				FY2019		FY2020						FY2021					FY2021
				1-12	1-3	1-6		1-9	1-12	1-3	Change	1-6	Change		1-9	Change	1-12	Change	1-12	Change
				YTD	YTD	YTD		YTD	YTD	YTD	(%)	YTD	(%)		YTD	(%)	YTD	(%)	YTD	(%)
Sales	588.9	144.5	305.7		464.8	633.3	130.3	(9.8)								631.0	(0.4)
	Domestic	437.6	101.9	204.6		303.2	409.1	94.9	(6.9)								393.7	(3.8)
		Oncology	240.9	55.3	113.4		169.4	232.3	57.9	+4.7								226.7	(2.4)
			Avastin	95.6	20.4	40.7		60.4	81.5	18.8	(7.8)								60.5	(25.8)
			Tecentriq	20.6	7.8	16.6		25.5	37.5	14.1	+80.8								49.2	+31.2
			Perjeta	30.7	8.3	16.7		24.8	33.5	7.4	(10.8)								31.8	(5.1)
			Alecensa	23.0	5.6	12.3		18.7	26.0	6.0	+7.1								27.0	+3.8
			Kadcyla	9.0	2.1	4.6		7.1	10.2	3.2	+52.4								13.3	+30.4
			Herceptin	26.7	4.5	8.6		12.3	15.9	2.6	(42.2)								10.9	(31.4)
			Gazyva	3.6	1.0	2.1		3.2	4.6	1.0	0.0								5.7	+23.9
			Rituxan	11.9	1.9	3.7		5.5	7.2	1.2	(36.8)								5.2	(27.8)
			Xeloda	8.0	1.1	2.0		2.8	3.6	0.6	(45.5)								2.7	(25.0)
			Rozlytrek	0.0	0.0	0.1		0.2	0.4	0.1	-								0.9	+125.0
			Foundation Medicine	0.4	0.6	1.2		2.0	2.8	1.0	+66.7								7.2	+157.1
			Other products	11.3	2.0	4.9		6.9	9.1	1.8	(10.0)								12.3	+35.2
		Primary	196.6	46.6	91.2		133.8	176.8	36.9	(20.8)								167.0	(5.5)
			Hemlibra	25.2	7.9	16.1		24.6	34.1	8.8	+11.4								51.7	+51.6
			Actemra	41.8	9.5	19.1		28.6	39.3	9.2	(3.2)								38.5	(2.0)
			Edirol	36.7	8.8	18.3		24.2	27.8	2.9	(67.0)								17.3	(37.8)
			Mircera	22.2	4.2	8.5		12.9	17.5	3.4	(19.0)								11.7	(33.1)
			Bonviva	9.7	2.1	4.2		6.5	8.9	2.0	(4.8)								8.5	(4.5)
			CellCept	9.3	2.2	4.5		6.7	9.1	2.0	(9.1)								8.3	(8.8)
			Oxarol	6.9	1.4	3.1		4.7	6.4	1.4	0.0								5.5	(14.1)
			Enspryng	-	-	-		0.3	1.3	1.4	-								4.0	+207.7
			Tamiflu(Ordinary use)	7.4	0.6	0.7		0.7	0.8	(0.1)	-								0.8	0.0
			Tamiflu(Govt. stockpiles etc.)	3.2	2.6	2.6		3.0	3.7	1.2	(53.8)								1.2	(67.6)
			Other products	34.3	7.2	14.2		21.9	27.9	4.7	(34.7)								19.6	(29.7)
	Overseas	151.3	42.6	101.0		161.6	224.2	35.4	(16.9)								237.3	+5.8
			Hemlibra	3.6	8.6	16.4		21.5	26.1	8.5	(1.2)								89.7	+243.7
			To Roche	3.3	8.2	15.7		20.4	24.6	8.0	(2.4)								88.0	+257.7
			Actemra	88.3	24.1	60.6		97.6	134.4	17.4	(27.8)								85.3	(36.5)
			To Roche	86.5	23.5	59.4		96.0	132.0	16.9	(28.1)								83.0	(37.1)
			Alecensa	45.3	6.2	16.8		30.7	44.3	6.0	(3.2)								44.2	(0.2)
			To Roche	44.6	5.9	16.2		29.8	43.0	5.6	(5.1)								42.5	(1.2)
			Enspryng	-	0.1	0.4		1.6	5.6	-	-								3.9	(30.4)
			To Roche	-	0.1	0.4		1.6	5.6	-	-								3.9	(30.4)
			Neutrogin	9.9	2.5	4.5		6.8	9.0	2.2	(12.0)								8.7	(3.3)
			Other products	4.2	1.1	2.2		3.4	4.8	1.2	+9.1								5.4	+12.5
Royalties and other operating income	97.3	34.9	62.5		111.7	153.6	38.6	+10.6								169.0	+10.0
	Royalty and profit-sharing income	76.5	26.4	53.5		89.1	129.6	36.6	+38.6								163.0	+25.8
	Other operating income	20.8	8.5	9.0		22.6	24.1	2.0	(76.5)								6.0	(75.1)
Revenues	686.2	179.4	368.1		576.5	786.9	168.8	(5.9)								800.0	+1.7
	Domestic	444.0	109.5	212.2		312.8	419.0	95.3	(13.0)								394.2	(5.9)
	Overseas	242.2	69.9	155.9		263.7	368.0	73.6	+5.3								405.8	+10.3

From the 1st Quarter of FY2021, sales for Foundation Medicine is included "Oncology", instead of "Others" until FY2020.

Also sales for products included "Bone and Joint", "Renal Diseases", "Others" until FY2020, are included "Primary" from the 1st Quarter of FY2021.

	Chugai Pharmaceutical Co., Ltd. (4519) Supplementary Materials for Consolidated Financial Results for the 1st quarter of FY2021(IFRS)	8
Financial position
																(Billions of yen)
		Actual		Actual							Actual
		FY2019		FY2020							FY2021
		Dec. 31	Mar. 31	Jun. 30	Sep. 30	Dec. 31	Mar. 31	vs. Mar. 31, 2020	vs. Dec. 31, 2020	Jun. 30	vs. Jun. 30, 2020	vs. Dec. 31, 2020	Sep. 30	vs. Sep. 30, 2020	vs. Dec. 31, 2020	Dec. 31	vs. Dec. 31, 2020
Trade accounts receivable	139.6	150.1	169.2	172.6	195.6	138.4	(11.7)	(57.2)
Inventories	168.1	174.4	172.0	179.6	183.9	184.7	10.3	0.8
Trade accounts payable	(47.7)	(51.3)	(44.7)	(45.2)	(58.3)	(42.1)	9.2	16.2
Other net working capital	(22.9)	(21.5)	8.5	(18.4)	(21.2)	0.3	21.8	21.5
	Net working capital	237.2	251.6	305.0	288.5	300.0	281.3	29.7	(18.7)
Property, plant and equipment	255.6	277.4	275.3	288.3	289.2	291.4	14.0	2.2
Right-of-use assets	9.7	8.4	7.7	9.0	8.3	7.4	(1.0)	(0.9)
Intangible assets	23.5	23.8	24.0	23.8	23.9	26.0	2.2	2.1
Other long-term assets - net	21.0	24.9	24.4	24.1	24.6	25.5	0.6	0.9
	Long-term net operating assets	309.8	334.5	331.3	345.1	346.0	350.3	15.8	4.3
	Net operating assets	547.0	586.1	636.3	633.6	646.0	631.6	45.5	(14.4)
Debt	-	-	-	-	-	-	-	-
Marketable securities	129.1	134.0	94.1	136.1	166.3	181.3	47.3	15.0
Cash and cash equivalents	203.9	138.7	196.6	182.7	212.3	162.0	23.3	(50.3)
	Net cash	333.1	272.7	290.7	318.8	378.6	343.4	70.7	(35.2)
Other non-operating assets - net	(26.1)	(4.7)	(21.1)	(27.2)	(44.6)	7.7	12.4	52.3
	Net non-operating assets	307.0	268.0	269.6	291.7	334.0	351.0	83.0	17.0
	Total net assets	854.0	854.1	905.9	925.3	980.0	982.6	128.5	2.6
Total net assets
	Total assets	1,058.9	1,045.6	1,072.1	1,136.1	1,235.5	1,144.6	99.0	(90.9)
	Total liabilities	(204.9)	(191.5)	(166.2)	(210.8)	(255.5)	(162.0)	29.5	93.5
Attributable to
	Chugai shareholders	854.0	854.1	905.9	925.3	980.0	982.6	128.5	2.6
	Non-controlling interests	-	-	-	-	-	-	-	-

Trade accounts receivable: trade receivable and notes receivable

Trade accounts payable: trade payable and notes payable

Other net working capital: accrued receivable (other receivable), accrued payable (other payable), accrued expenses (other current liabilities) etc.

Other long-termassets-net:long-term prepaid expenses, long-term provisions etc.

Other non-operatingassets-net: deferred income tax assets, current income tax liabilities etc.

Net operating assets (NOA) and Net assets:

The consolidated balance sheet has been prepared in accordance with International Accounting Standards (IAS) No. 1, "Presentation of Financial Statements." On the other hand, Net operating assets (NOA) and Net assets are a reconfiguration of the consolidated balance sheet as internal indicators and are identical to the indicators disclosed by Roche. Furthermore, no items from Net operating assets (NOA) and Net assets of IFRS have been excluded, as the Core results concept only applies to the income statement.

Net operating assets (NOA):

Net operating assets allow for an assessment of the Group's operating performance of the business independently from financing and tax activities. Net operating assets are calculated as net working capital, long-term net operating assets that includes property, plant and equipment, right-of-use assets, intangible assets etc. minus provisions.

Chugai Pharmaceutical Co., Ltd. (4519) Supplementary Materials for Consolidated Financial Results for the 1st quarter of FY2021(IFRS)	9
Cash flows
											(Billions of yen)
	Actual		Actual					Actual
	FY2019		FY2020					FY2021
	1-12	1-3	1-6		1-9	1-12	1-3	1-6		1-9		1-12
	YTD	YTD	YTD		YTD	YTD	YTD	YTD		YTD		YTD
Operating profit - IFRS basis	210.6	72.4	140.6		227.3	301.2	64.0
Depreciation and impairment of property, plant and equipment	19.0	5.2	10.5		16.1	22.3	5.3
Depreciation and impairment of right-of-use assets	6.0	1.5	2.8		4.2	5.5	1.3
Amortization and impairment of intangible assets	5.3	0.9	1.6		2.3	3.6	0.7
Other cash adjustment on operating profit	4.3	1.1	2.0		3.1	2.9	0.9
Operating profit, net of operating cash adjustments	245.2	81.0	157.6		253.0	335.5	72.2
(Increase) decrease in trade accounts receivable	11.1	(10.5)	(29.5)		(32.9)	(55.9)	57.4
(Increase) decrease in inventories	(9.0)	(6.8)	3.6		6.4	3.3	(1.0)
Increase (decrease) in trade accounts payable	11.8	3.7	(3.0)		(2.5)	10.5	(16.5)
Change in other net working capital etc.	(7.7)	(21.2)	(32.4)		(27.1)	(22.3)	0.3
Total (increase) decrease in net working capital etc.	6.2	(34.8)	(61.4)		(56.1)	(64.4)	40.2
Investment in property, plant and equipment	(53.0)	(11.1)	(40.6)		(47.3)	(57.0)	(28.9)
Lease liabilities paid	(8.9)	(2.1)	(4.2)		(6.3)	(8.4)	(2.2)
Investment in intangible assets	(8.2)	(1.2)	(2.3)		(3.1)	(4.3)	(2.9)
Operating free cash flows	181.4	31.8	49.0		140.3	201.2	78.3
as % of revenues	26.4%	17.7%	13.3%		24.3%	25.6%	46.4%
Treasury activities (interest income/expenses, foreign exchange gains/losses etc.)	(0.9)	0.6	2.2		3.7	2.5	(2.5)
Settlement for transfer pricing taxation	(3.1)	(0.5)	(0.9)		(1.1)	(1.5)	-
Tax paid	(34.8)	(41.0)	(41.9)		(66.4)	(66.8)	(63.3)
Free cash flows	142.6	(9.1)	8.4		76.4	135.4	12.4
Dividends paid	(56.4)	(50.1)	(50.4)		(91.2)	(91.4)	(49.0)
Transaction in own equity instruments	0.7	0.3	0.3		0.4	0.4	0.2
Purchase of non-controlling interests	(2.3)	-	-		-	-	-
Net effect of currency translation on net cash	(0.8)	(1.4)	(0.8)		0.2	1.2	1.2
Net change in net cash	83.9	(60.4)	(42.4)		(14.3)	45.5	(35.2)

Other cash adjustment on operating profit: adjustments for all non-cash income and expense items other than amortization expenses and impairment included in operating profit (such as loss on inventory differences, reserve for doubtful accounts, stock option expenses, loss on asset retirement, and increase/decrease in reserves) as well as all non-operating income and expense cash flows relating to net operating assets (NOA) including proceeds from the sales of assets and reserve payments.

Operating free cash flow (Operating FCF): pretax cash flow after adjusting changes in working capital and operating investments in assets (tangible and intangible) to "operating profit, net of operating cash adjustments," which shows the company's cash generation ability from operating activities.

Free cash flow (FCF): the ability to generate net cash from a management perspective after deducting tax, dividends, and other payments from operating FCF.

Net change in net cash: dividends paid, increases and decreases in marketable securities and interest-bearing debt、changes in equity are included.

The concepts of operating profit, operating FCF and Net operating assets (NOA) presented in the previous page are mutually consistent. Free cash flow (FCF):

The consolidated statement of cash flows has been prepared in accordance with International Accounting Standard (IAS) No. 7, "Statement of Cash Flows." FCF is a reconfiguration of the consolidated statement of cash flows as internal indicators and is identical to the indicators disclosed by Roche. Furthermore, no items from FCF have been excluded, as the Core results concept only applies to the income statement.

Chugai Pharmaceutical Co., Ltd. (4519) Supplementary Materials for Consolidated Financial Results for the 1st quarter of FY2021(IFRS)

10

Key Performance indicators

		Actual		Actual			Actual		Forecast
						(Feb 4th
											announced)
		2019		2020			2021		2021
		1-12	1-3	1-6	1-9	1-12	1-3	1-6	1-9	1-12	1-12
	Units	As of Dec. 31	As of Mar. 31	As of Jun. 30	As of Sep. 30	As of Dec. 31	As of Mar. 31	As of Jun. 30	As of Sep. 30	As of Dec. 31	As of Dec. 31
Total indicator
Core return on invested capital (Core ROIC)	%	31.9	9.5	17.8	28.4	37.3	7.5
Return on invested capital (ROIC)	%	30.1	9.3	17.5	27.9	36.5	7.4
Ratio of profit to total assets (ROA)	%	15.8	4.9	9.6	14.8	18.7	4.0
Ratio of equity attributable to
%	80.6	81.7	84.5	81.4	79.3	85.8
Chugai shareholders
Ratio of equity attributable to	%	521.2	654.7	883.9	682.2	732.2	644.8
Chugai shareholders (stock price base)
Price book value ratio（PBR)	times	6.5	8.0	10.5	8.4	9.2	7.5
Ratio of net income to equity attributable to	%	19.6	6.0	11.6	18.3	23.4	4.8
Chugai shareholders (ROE)
Margin indicator
ROS	%	32.8	41.3	39.0	40.2	39.1	38.7				40.0
COS ratio（vs. Prod. sales）	%	45.0	42.2	42.9	43.1	43.0	42.2				40.0
M&D cost ratio	%	10.7	8.6	8.8	8.5	9.1	9.4
R&D cost ratio	%	14.9	13.9	14.4	14.3	14.4	17.0				16.4
G&A cost ratio	%	3.0	2.2	2.2	2.3	2.8	2.3
Turn over indicator
Total asset turnorver	%	68.9	17.1	34.5	52.5	68.6	14.2
Working capital turnover	%	128.7	31.7	62.2	97.7	131.9	26.4
Inventory turnover	Months	7.6	8.5	7.8	8.0	8.1	10.0
Receivables turnover	Months	2.8	3.1	3.3	3.3	3.7	3.2
Payables turnover	Months	2.2	2.5	2.0	2.0	2.6	2.3
Fixed asset turnover	%	250.0	60.0	123.6	189.1	257.9	52.2
PP&E turnover	%	287.3	67.3	138.7	212.0	288.9	58.2
intangible assets turnover	%	2,968.0	757.7	1,548.1	2,436.2	3,319.0	676.6
Dividend / per stock indicator
Dividends per share (Half year)	Yen	48				75					30
Dividends per share (Year end)	Yen	92				30					30
Dividends per share (Full year)	Yen	140				-					60
Core earnings per share (diluted)	Yen	101.93	32.04	63.51	100.68	133.39	29.42				141.00
Core payout ratio (%)	%	45.8				41.2					42.6
Equity per share attributable	Yen	519.91	519.90	551.13	562.88	596.16	597.67
to Chugai shareholders (BPS)
Ratio of dividends to equity attributable to	%	9.5				9.9
Chugai shareholders (DOE)
Cashflow indicator
Cash conversion cycle（CCC）	Months	8.3	9.1	9.1	9.4	9.2	10.9
Net cash turnover period	Months	5.8	4.6	4.7	5.0	5.8	6.1
Number of employees		7,394	7,400	7,536	7,559	7,555	7,490
Investment on property, plant and equipment	Billions of yen	54.0	27.3	38.7	67.9	75.2	7.4				79.5
Depreciation	Billions of yen	17.8	5.2	10.5	16.1	22.0	5.3				21.0
Investment on intangible assets	Billions of yen	6.1	1.1	2.1	2.5	3.9	2.9
Amortization	Billions of yen	2.6	0.7	1.5	2.2	2.9	0.7

Core ROIC：Core net operting profit after taxes / Net operating assets (Core ROIC is calculated by using Core Income taxes)

ROIC: Net operating profit after taxes / Net operating assets (Net operating profit after taxes = Operating profit - income taxes)

ROA: Net income / total assets, ROE: Net income attributable for Chugai shareholders / Equity attributable to Chugai shareholders

Total asset turnorver: Revenues / Total asset, CCC：[Trade accounts receivable/Sales＋（Inventories - Trade accounts payable）/Cost of sales]* passed months Net cash turnover period：Net cash/Revenue* passed months

Core ROIC, ROIC, ROA, ROE, total asset turnover, working capital turnover, fixed asset turnover, PP&E turnover, and intangible assets turnover are not annualized The Adjusted figures are used for calculating average NOA for Core ROIC and ROIC

Effective July 1, 2020, Chugai Pharmaceutical Co., Ltd. ("Chugai") implemented a three-for-one stock split of its common stock.

The dividend for the fiscal year ended December 31, 2019 and the second quarter of the fiscal year 2020 presents the amount prior to the stock split.

The annual dividend per share for the fiscal year ended December 31, 2020 is not stated because the amounts cannot be simply combined due to the implementation of the stock split. The annual dividend per share is ¥165 when calculated based on the assumption of no stock split, and ¥55 when calculated with the stock split taken into account.

Core EPS and BPS presents the amount after the stock split.

Chugai Pharmaceutical Co., Ltd. (4519) Supplementary Materials for the 1st quarter of FY2021 (IFRS) 11

Development pipeline (as of April 22, 2021)

	Origin	Indication	Stage	Generic name
Development code	Overseas name	Product name	Mode of Action
# Additional indication	(Date)
	(Collaborator)	Dosage form
Oncology
RG7596	Roche/Seattle Genetics	Relapsed or refractory diffuse large B-cell	Approved	polatuzumab vedotin	Anti-CD79bantibody-drug conjugate
	Polivy	lymphoma (DLBCL)	(21/03)	Polivy
				Injection
		DLBCL	Phase III
		#
RG7446	Roche	Non-small cell lung cancer (NSCLC)	Phase III	atezolizumab	Engineered anti-PD-L1 monoclonal antibody
	Tecentriq	(adjuvant)		Tecentriq
		#		Injection
		NSCLC (neoadjuvant)	Phase III
		#
		NSCLC (stage III)	Phase III
		#	(in combination with
			RG6058)
		Urothelial carcinoma	Phase III
		#
		Renal cell carcinoma (adjuvant)	Phase III
		#
	Roche	Renal cell carcinoma (2nd Line)	Phase III
	Tecentriq	#	(in combination with
	(Takeda)		cabozantinib)
	Roche	Early breast cancer	Phase III
	Tecentriq	#
		Ovarian cancer	Phase III
		#	(in combination with
			RG435)
		Hepatocellular carcinoma (HCC) (adjuvant)	Phase III
		#	(in combination with
			RG435)
		HCC (intermediate stage)	Phase III
		#	(in combination with
			RG435)
		Head and neck carcinoma (adjuvant)	Phase III
		#

Chugai Pharmaceutical Co., Ltd. (4519) Supplementary Materials for the 1st quarter of FY2021 (IFRS) 12

	Origin	Indication	Stage	Generic name
Development code	Overseas name	Product name	Mode of Action
# Additional indication	(Date)
	(Collaborator)	Dosage form
		Esophageal cancer	Phase III
		#	(in combination with
			RG6058)
		Pancreatic adenocarcinoma	Phase I
		#	Morpheus platform
			(in combination with
			RG1569 or RG6058)
RG435	Roche	HCC (adjuvant)	Phase III	bevacizumab	Anti-VEGF (Vascular Endothelial Growth
	Avastin	#	(in combination with	Avastin	Factor) humanized monoclonal antibody
			RG7446)	Injection
		HCC (intermediate stage)	Phase III
		#	(in combination with
			RG7446)
		Small cell lung cancer (SCLC)	Phase III
		#	(in combination with
			RG7446)
RG7440	Roche/Array BioPharma	Breast cancer	Phase III	ipatasertib	AKT inhibitor
				Oral
		Prostate cancer	Phase III
RG6264	Roche	Breast cancer	Phase III	trastuzumab/pertuzumab	Anti-HER2 humanized monoclonal antibody/
	Phesgo	(Fixed-dose combination, subcutaneous			HER2 dimerization inhibitory humanized
		injection)		Injection	monoclonal antibody
AF802 / RG7853	In-house	NSCLC (adjuvant)	Phase III	alectinib	ALK inhibitor
	Alecensa	#		Alecensa
	(Roche)			Oral
RG6058	Roche	SCLC	Phase III	tiragolumab	Anti-TIGIT human monoclonal antibody
			(in combination with
			RG7446)	Injection
		NSCLC	Phase III
			(in combination with
			RG7446)
		NSCLC (stage III)	Phase III
			(in combination with
			RG7446)

Chugai Pharmaceutical Co., Ltd. (4519) Supplementary Materials for the 1st quarter of FY2021 (IFRS) 13

	Origin	Indication	Stage	Generic name
Development code	Overseas name	Product name		Mode of Action
# Additional indication	(Date)
	(Collaborator)	Dosage form
		Esophageal cancer	Phase III
			(in combination with
			RG7446)
RG6171	Roche	Breast cancer	Phase III	giredestrant	SERD (Selective Estrogen Receptor Degrader)
				Oral
OBP-301	Oncolys BioPharma	Esophageal cancer	Phase II		Oncolytic type 5 adenovirus
				Injection
		HCC	Phase I
			(in combination with
			RG7446 and RG435)
GC33	In-house	HCC	Phase I	codrituzumab	Anti-Glypican-3	humanized	monoclonal
					antibody
				Injection
ERY974	In-house	Solid tumors	Phase I		Anti-Glypican-3/CD3 bispecific antibody
				Injection
RG7421	Roche/Exelixis	Solid tumors	Phase I	cobimetinib	MEK inhibitor
	Cotellic
				Oral
RG7802	Roche	Solid tumors	Phase I	cibisatamab	Anti-CEA/CD3 bispecific antibody
				Injection
RG7828	Roche	Hematologic tumors	Phase I	mosunetuzumab	Anti-CD20/CD3 bispecific antibody
				Injection
RG6026	Roche	Hematologic tumors	Phase I	glofitamab	Anti-CD20/CD3 bispecific antibody
				Injection
AMY109	In-house	Solid tumors	Phase I		‒
				Injection
STA551	In-house	Solid tumors	Phase I		Anti-CD137 agonistic Switch antibody
				Injection

Chugai Pharmaceutical Co., Ltd. (4519) Supplementary Materials for the 1st quarter of FY2021 (IFRS) 14

	Origin	Indication	Stage	Generic name
Development code	Overseas name	Product name	Mode of Action
# Additional indication	(Date)
	(Collaborator)	Dosage form
SPYK04	In-house	Solid tumors	Phase I			‒
				Oral
RG6194	Roche	Solid tumors	Phase I			Anti-HER2/CD3 bispecific antibody
				Injection
Bone and Joint Diseases
ED-71	In-house	Osteoporosis	Approved	eldecalcitol		Activated vitamin D3 agent
			(20/12)	Edirol
			China	Oral
NRD101	In-house	Knee osteoarthritis / Shoulder periarthritis	Phase III	purified	sodium	Sodium hyaluronate
			(China)	hyaluronate
				Suvenyl
				Injection
Renal Diseases
EOS789	In-house	Hyperphosphatemia	Phase I			NaPi-IIb,PiT-1,PiT-2 inhibitor
				Oral
Autoimmune Diseases
RG7880	Roche	Inflammatory bowel disease	Phase I	efmarodocokin alfa		Human IL-22 fusion protein
				Injection
Neurology
SA237 / RG6168	In-house	Neuromyelitis optica spectrum disorder	Filed	satralizumab		pH-dependent binding humanized anti-IL-6
	Enspryng	(NMOSD)	(19/08)	Enspryng		receptor monoclonal antibody
	(Roche)		EU	Injection
RG7916	Roche/PTC Therapeutics	Spinal muscular atrophy (SMA)	Filed	risdiplam		SMN2 splicing modifier
	Evrysdi		(20/10)
				Oral
RG1450	Roche/MorphoSys	Alzheimer's disease	Phase III	gantenerumab		Anti-amyloid-beta human monoclonal antibody
				Injection
RG6042	Roche/Ionis	Huntington's disease	Phase III	tominersen		Antisense oligonucleotide targeting HTT mRNA
	Pharmaceuticals
				Injection

Chugai Pharmaceutical Co., Ltd. (4519) Supplementary Materials for the 1st quarter of FY2021 (IFRS) 15

	Origin	Indication	Stage	Generic name
Development code	Overseas name	Product name	Mode of Action
# Additional indication	(Date)
	(Collaborator)	Dosage form
RG7906	Roche	Schizophrenia	Phase II	ralmitaront	Partial TAAR1 agonist
				Oral
RG7935	Roche/Prothena	Parkinson's disease	Phase I	prasinezumab	Anti-α-synuclein monoclonal antibody
				Injection
GYM329 / RG6237	In-house	Neuromuscular disease	Phase I		Anti-latent myostatin sweeping antibody
	(Roche)			Injection
RG6100	Roche/AC Immune	Alzheimer's disease	Phase I	semorinemab	Anti-tau humanized monoclonal antibody
				injection
Other diseases
MRA / RG1569	In-house	COVID-19 pneumonia	Phase III*	tocilizumab	Humanized anti-humanIL-6 receptor
	Actemra/RoActemra (EU)	#	(Japan)	Actemra	monoclonal
				Injection	antibody
RG7716	Roche	Diabetic macular edema	Phase III	faricimab	Anti-VEGF/Ang2 bispecific antibody
		Neovascular age related macular	Phase III	Injection
		degeneration (nAMD)
		Retinal vein occlusion	Phase III
ACE910 / RG6013	In-house	Acquired hemophilia A	Phase III	emicizumab	Anti-coagulation factor IXa/X humanized
	Hemlibra	#	(Japan)	Hemlibra	bispecific monoclonal antibody
				Injection
SKY59 / RG6107	In-house	Paroxysmal nocturnal hemoglobinuria	Phase III	crovalimab	Anti-C5 recycling antibody
		(PNH)
	(Roche)			Injection
NXT007	In-house	Hemophilia A	Phase l/II		Anti-coagulation factor IXa/X bispecific
					antibody
				Injection
PCO371	In-house	Hypoparathyroidism	Phase I		PTH1 receptor agonist
				Oral
AMY109	In-house	Endometriosis	Phase l		‒
				Injection

Chugai Pharmaceutical Co., Ltd. (4519) Supplementary Materials for the 1st quarter of FY2021 (IFRS) 16

	Origin	Indication	Stage	Generic name
Development code	Overseas name	Product name	Mode of Action
# Additional indication	(Date)
	(Collaborator)	Dosage form
RG6413/RG6412	Roche/Regeneron	COVID-19	Phase l	casirivimab/imdevimab	SARS-CoV-2 Neutralizing antibody
	Pharmaceuticals				cocktail
				Injection

In principle, completion of first dose is regarded as the start of clinical studies in each phase. * Roche is conducting global Phase III studies of Actemra/RoActemra against COVID-19 pneumonia separately.

Changes from the last announcement on February 4, 2021

Oncology
- RG7596	Filed (Relapsed or refractory diffuse large B-cell lymphoma) → Approved
- RG7446	Phase III (HCC (intermediate stage) / in combination with RG435: development started)
- RG435	Phase III (HCC (intermediate stage) / in combination with RG7446: development started)
Other diseases
- RG7716	Phase III (Retinal vein occlusion: development started)
- RG6413/RG6412	Phase I (COVID-19: development started)

R&D Activities

For the changes during the FY2021 (January 1 - March 31), please refer to page 4 of "CONSOLIDATED FINANCIAL STATEMENTS (IFRS) (Non-Audited) (for the first quarter of the fiscal year 2021)."

Chugai Pharmaceutical Co., Ltd. (4519) Supplementary Materials for the 1st quarter of FY2021 (IFRS) 17

Major Chugai originated developments licensed out to 3rd party excluding Roche

Development code			Generic name	Licensee
Indication	Stage	Product name	Mode of Action
in Chugai	(granted right )
		Dosage form
CIM331	Atopic dermatitis	Filled	nemolizumab	Maruho	Anti-IL-31 receptor A humanized
		(20/Q3)		(rights for development and marketing in the	monoclonal antibody
		Japan	Injection	skin disease area for the Japanese market)
		Phase III		Galderma
		(global)		(exclusive global license for the
				development and marketing excluding
				Japan and Taiwan)
	Prurigo nodularis	Phase III		Galderma
		(global)		(exclusive global license for the
				development and marketing excluding
				Japan and Taiwan)
		Phase II/III		Maruho
		(Japan)		(rights for development and marketing in
				the skin disease area for the Japanese
				market)
OWL833	Type 2 diabetes	Phase I		Eli Lilly and Company	Oral non-peptidicGLP-1 receptor
				(worldwide development and	agonist
			Oral	commercialization rights)

Chugai Pharmaceutical Co., Ltd. (4519) Supplementary Materials for the 1st quarter of FY2021 (IFRS) 18

Major clinical trials in oncology field

Treatment	Expected Indication		Study design	Study name	Stage	Planned filing year
	NSCLC [1st line]		PD-L1 positive: Tecentriq ± RG6058	SKYSCRAPER-01	Phase III	2023
	NSCLC [stage III]		Tecentriq + RG6058 vs. durvalumab	SKYSCRAPER-03	Phase III	2024 and beyond
	NSCLC [2nd line]		Tecentriq + cabozantinib vs. docetaxel	CONTACT-01	Phase III	2023
	NSCLC (neoadjuvant)		Chemo ± Tecentriq	IMpower030	Phase III	2023
	NSCLC (adjuvant)		Tecentriq vs. best supportive care	IMpower010	Phase III	2021
	SCLC		Tecentriq + chemo ± Avastin	BEAT-SC	Phase III	2023
		Tecentriq + chemo ± RG6058	SKYSCRAPER-02	Phase III	2022
	Urothelial carcinoma (UC)		Tecentriq ± chemo vs. chemo	IMvigor130	Phase III	2022
RG7446	Renal cell carcinoma (adjuvant)		Tecentriq	IMmotion010	Phase III	2022
Renal cell carcinoma [2nd line]		cabozantinib ± Tecentriq	CONTACT-03	Phase III	2023d
(Tecentriq)
Early breast cancer		TNBC (adjuvant): paclitaxel ± Tecentriq	IMpassion030	Phase III	2024 and beyond
		TNBC (neoadjuvant): nab-paclitaxel ± Tecentriq	IMpassion031	Phase III
	Ovarian cancer		carboplatin + paclitaxel + Avastin ± Tecentriq	IMagyn050	Phase III	2022
	HCC (adjuvant)		Tecentriq + Avastin vs. active surveillance	IMbrave050	Phase III	2022
	HCC (intermediate stage)		Tecentriq + Avastin + TACE vs. TACE	TALENTACE	Phase III	2024 and beyond
	Head and neck carcinoma (adjuvant)		Tecentriq	IMvoke010	Phase III	2022
	Esophageal cancer		Tecentriq + RG6058 vs. Tecentriq vs. placebo	SKYSCRAPER-07	Phase III	2024 and beyond
	Pancreatic adenocarcinoma [1st line]		Tecentriq + Actemra vs. gemcitabine + nab-paclitaxel	Morpheus-PC	Phase I	⁻
		Tecentriq + RG6058 vs. gemcitabine + nab-paclitaxel	⁻
RG7440	Prostate cancer		castration-resistant: abiraterone ± RG7440	IPATential150	Phase III	2022
(ipatasertib)	Breast cancer		fulvestrant + palbociclib ± RG7440	IPATunity150	Phase Ib/III	2024 and beyond
RG7596	DLBCL		Rituxan + Chemo ± RG7596	POLARIX	Phase III	2021
(polatuzumab vedotin)
RG6264	Breast cancer		RG6264 (SC) + chemo vs. Herceptin (IV) + Perjeta (IV) + chemo	FeDeriCa	Phase III	2021
AF802 (Alecensa)	NSCLC (adjuvant)		ALK fusion-positive: Alecensa vs. chemo	ALINA	Phase III	2023
RG6171 / SERD	Breast cancer		HR positive: RG6171 + palbocicilib ± Letrozole	-	Phase III	2024 and beyond
OBP-301	Esophageal cancer		OBP-301 + radiotherapy	-	Phase II*	2024 and beyond

TNBC: triple negative breast cancer, HR: hormone receptor, TACE: transarterial chemoembolization, *: domestic

		Chugai Pharmaceutical Co., Ltd. (4519) Supplementary Materials for the 1st quarter of FY2021 (IFRS) 19
FoudationOne CDx Cancer Genomic Profile: companion diagnostic indications (as of April 22, 2021)
Alterations	Cancer type	Relevant drugs
Activated EGFR gene alterations	NSCLC	afatinib dimaleate, erlotinib hydrochloride, gefitinib, osimertinib mesylate
EGFR exon 20 T790M alterations		osimertinib mesylate
ALK fusion genes		alectinib hydrochloride, crizotinib, ceritinib
ROS1 fusion genes		entrectinib
MET exon 14 skipping alterations		capmatinib hydrochloride hydrate
BRAF V600E and V600K alterations	Malignant melanoma	dabrafenib mesylate, trametinib dimethyl sulfoxide, vemurafenib
ERBB2 copy number alterations (HER2 gene	Breast cancer	trastuzumab (genetical recombination)
amplification positive)
KRAS/NRAS wild-type	Colorectal cancer	cetuximab (genetical recombination), panitumumab (genetical recombination)
Microsatellite Instability-High	nivolumab (genetical recombination)
Microsatellite Instability-High	Solid tumors	pembrolizumab (genetical recombination)
NTRK1/2/3 fusion gene	entrectinib, larotrectinib sulfate
BRCA1/2 alterations	Ovarian cancer	olaparib
BRCA1/2 alterations	Prostate cancer	olaparib
FGFR2 fusion genes	Biliary Tract Cancer	pemigatinib
* Underlined are the companion diagnostic features and relevant drugs currently	under application for regulatory approval
FoudationOne Liquid CDx Cancer Genomic Profile: companion diagnostic indications (as of April 22 2021)
Alterations	Cancer type	Relevant drugs
Activated EGFR gene alterations	NSCLC	afatinib dimaleate, erlotinib hydrochloride, gefitinib, osimertinib mesylate
EGFR exon 20 T790M alterations		osimertinib mesylate
ALK fusion genes		alectinib hydrochloride, crizotinib, ceritinib
ROS1 fusion genes		entrectinib
NTRK1/2/3 fusion gene	Solid tumors	entrectinib